Higher Cerebrospinal Fluid Angiotensin-Converting Enzyme Levels in Neuroleptic-Treated Than in Drug-Free Patients With Schizophrenia
The aim of this study was to replicate our earlier finding of elevated angiotensin-converting enzyme (ACE) in cerebrospinal fluid (CSF) in schizophrenia and to elucidate the role of neuroleptic treatment in this phenomenon. Drug-free and medicated patients with acute schizophrenic psychoses, as well...
Gespeichert in:
| Veröffentlicht in: | Schizophrenia bulletin 1998-01, Vol.24 (3), p.391-397 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 397 |
|---|---|
| container_issue | 3 |
| container_start_page | 391 |
| container_title | Schizophrenia bulletin |
| container_volume | 24 |
| creator | Wahlbeck, Kristian Ahokas, Antti Miettinen, Kati Nikkilä, Heikki Rimón, Ranan |
| description | The aim of this study was to replicate our earlier finding of elevated angiotensin-converting enzyme (ACE) in cerebrospinal fluid (CSF) in schizophrenia and to elucidate the role of neuroleptic treatment in this phenomenon. Drug-free and medicated patients with acute schizophrenic psychoses, as well as healthy controls were recruited. Levels of ACE were measured in CSF and serum from 7 drug-free patients, 36 neuroleptic-treated patients, and 19 healthy control subjects. Although ACE levels in CSF did not differ between patients and controls, the drug-free patients showed significantly lower levels than the neuroleptic-treated patients. Serum ACE did not differ between groups. The elevation of CSF ACE may be more prominent in patients with deficit symptoms than in those with mainly psychotic symptoms.
The possible enhancement of CSF ACE production or solubility by neuroleptic treatment is discussed. Elevated ACE levels in CSF may, together with other possible factors, cause polydipsia, stimulate secretion of arginine vasopressin, and even affect neuron growth and differentiation in schizophrenic psychoses. |
| doi_str_mv | 10.1093/oxfordjournals.schbul.a033334 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_614379485</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>614379485</sourcerecordid><originalsourceid>FETCH-LOGICAL-a494t-9f249cd016de73b82479e470dd639c2f4b53368f9340aeb69aa293f0f2a15b0d3</originalsourceid><addsrcrecordid>eNp9kc2O0zAUhS0EGsrAIyBZCFYoxX_58YLFqExnkCpAooil5Tg3jUepE2xnRLvmwXHVzEhs8MaL-91j-XwIvaNkSYnkH4bf7eCbu2HyTvdhGUxXT_1SE56OeIIWtBR5RktCn6IFyasiKwsqnqMXIdwRQoUs2AW6kCWtCk4X6M-t3XXg8Qo81H4Io02peN1PtsFXbmeHCC5Yl60Gdw8-WrfD1-542APewD30AVuHv8Dkhx7GaE229aAjNHjbaXeaffLTLlt7APxNRwsuBvzTxg5_N509DmPnwVn9Ej1r01_g1Xxfoh_r6-3qNtt8vfm8utpkWkgRM9kyIU1DaNFAyeuKiVKCKEnTFFwa1oo657yoWskF0VAXUmsmeUtapmlek4Zfojfn3NEPvyYIUT3UqFJHvJSiyv8HMcbzvCgJS9DHM2RSZ8FDq0Zv99ofFCXqpEn9q0mdNalZU9p_PT8y1XtoHrdnL2n-dp7rYHTfeu2MDY8YE0yQ_BTz_ozpUasxHIxOikwPwUw-NRtVONYJVlxxSflfGxO0AQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>614379485</pqid></control><display><type>article</type><title>Higher Cerebrospinal Fluid Angiotensin-Converting Enzyme Levels in Neuroleptic-Treated Than in Drug-Free Patients With Schizophrenia</title><source>MEDLINE</source><source>PsycARTICLES</source><source>AUTh Library subscriptions: Oxford University Press</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Wahlbeck, Kristian ; Ahokas, Antti ; Miettinen, Kati ; Nikkilä, Heikki ; Rimón, Ranan</creator><creatorcontrib>Wahlbeck, Kristian ; Ahokas, Antti ; Miettinen, Kati ; Nikkilä, Heikki ; Rimón, Ranan</creatorcontrib><description>The aim of this study was to replicate our earlier finding of elevated angiotensin-converting enzyme (ACE) in cerebrospinal fluid (CSF) in schizophrenia and to elucidate the role of neuroleptic treatment in this phenomenon. Drug-free and medicated patients with acute schizophrenic psychoses, as well as healthy controls were recruited. Levels of ACE were measured in CSF and serum from 7 drug-free patients, 36 neuroleptic-treated patients, and 19 healthy control subjects. Although ACE levels in CSF did not differ between patients and controls, the drug-free patients showed significantly lower levels than the neuroleptic-treated patients. Serum ACE did not differ between groups. The elevation of CSF ACE may be more prominent in patients with deficit symptoms than in those with mainly psychotic symptoms.
The possible enhancement of CSF ACE production or solubility by neuroleptic treatment is discussed. Elevated ACE levels in CSF may, together with other possible factors, cause polydipsia, stimulate secretion of arginine vasopressin, and even affect neuron growth and differentiation in schizophrenic psychoses.</description><identifier>ISSN: 0586-7614</identifier><identifier>EISSN: 1745-1701</identifier><identifier>DOI: 10.1093/oxfordjournals.schbul.a033334</identifier><identifier>PMID: 9718631</identifier><identifier>CODEN: SCZBB3</identifier><language>eng</language><publisher>Oxford: National Institute of Mental Health</publisher><subject>Adult ; Analysis of Variance ; Angiotensin ; Antipsychotic Agents - adverse effects ; Antipsychotic Agents - pharmacology ; Biological and medical sciences ; Blood-Brain Barrier - drug effects ; Case-Control Studies ; Cerebrospinal Fluid ; Drug Therapy ; Enzymes ; Female ; Human ; Humans ; Male ; Medical sciences ; Middle Aged ; Neuroleptic Drugs ; Neuropharmacology ; Peptidyl-Dipeptidase A - cerebrospinal fluid ; Peptidyl-Dipeptidase A - drug effects ; Pharmacology. Drug treatments ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Schizoaffective Disorder ; Schizophrenia ; Schizophrenia - cerebrospinal fluid ; Schizophrenia - drug therapy ; Schizophrenia - enzymology ; Schizophreniform Disorder</subject><ispartof>Schizophrenia bulletin, 1998-01, Vol.24 (3), p.391-397</ispartof><rights>1998 INIST-CNRS</rights><rights>Copyright Superintendent of Documents 1998</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a494t-9f249cd016de73b82479e470dd639c2f4b53368f9340aeb69aa293f0f2a15b0d3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2424054$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9718631$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wahlbeck, Kristian</creatorcontrib><creatorcontrib>Ahokas, Antti</creatorcontrib><creatorcontrib>Miettinen, Kati</creatorcontrib><creatorcontrib>Nikkilä, Heikki</creatorcontrib><creatorcontrib>Rimón, Ranan</creatorcontrib><title>Higher Cerebrospinal Fluid Angiotensin-Converting Enzyme Levels in Neuroleptic-Treated Than in Drug-Free Patients With Schizophrenia</title><title>Schizophrenia bulletin</title><addtitle>Schizophr Bull</addtitle><description>The aim of this study was to replicate our earlier finding of elevated angiotensin-converting enzyme (ACE) in cerebrospinal fluid (CSF) in schizophrenia and to elucidate the role of neuroleptic treatment in this phenomenon. Drug-free and medicated patients with acute schizophrenic psychoses, as well as healthy controls were recruited. Levels of ACE were measured in CSF and serum from 7 drug-free patients, 36 neuroleptic-treated patients, and 19 healthy control subjects. Although ACE levels in CSF did not differ between patients and controls, the drug-free patients showed significantly lower levels than the neuroleptic-treated patients. Serum ACE did not differ between groups. The elevation of CSF ACE may be more prominent in patients with deficit symptoms than in those with mainly psychotic symptoms.
The possible enhancement of CSF ACE production or solubility by neuroleptic treatment is discussed. Elevated ACE levels in CSF may, together with other possible factors, cause polydipsia, stimulate secretion of arginine vasopressin, and even affect neuron growth and differentiation in schizophrenic psychoses.</description><subject>Adult</subject><subject>Analysis of Variance</subject><subject>Angiotensin</subject><subject>Antipsychotic Agents - adverse effects</subject><subject>Antipsychotic Agents - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Blood-Brain Barrier - drug effects</subject><subject>Case-Control Studies</subject><subject>Cerebrospinal Fluid</subject><subject>Drug Therapy</subject><subject>Enzymes</subject><subject>Female</subject><subject>Human</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neuroleptic Drugs</subject><subject>Neuropharmacology</subject><subject>Peptidyl-Dipeptidase A - cerebrospinal fluid</subject><subject>Peptidyl-Dipeptidase A - drug effects</subject><subject>Pharmacology. Drug treatments</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Schizoaffective Disorder</subject><subject>Schizophrenia</subject><subject>Schizophrenia - cerebrospinal fluid</subject><subject>Schizophrenia - drug therapy</subject><subject>Schizophrenia - enzymology</subject><subject>Schizophreniform Disorder</subject><issn>0586-7614</issn><issn>1745-1701</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc2O0zAUhS0EGsrAIyBZCFYoxX_58YLFqExnkCpAooil5Tg3jUepE2xnRLvmwXHVzEhs8MaL-91j-XwIvaNkSYnkH4bf7eCbu2HyTvdhGUxXT_1SE56OeIIWtBR5RktCn6IFyasiKwsqnqMXIdwRQoUs2AW6kCWtCk4X6M-t3XXg8Qo81H4Io02peN1PtsFXbmeHCC5Yl60Gdw8-WrfD1-542APewD30AVuHv8Dkhx7GaE229aAjNHjbaXeaffLTLlt7APxNRwsuBvzTxg5_N509DmPnwVn9Ej1r01_g1Xxfoh_r6-3qNtt8vfm8utpkWkgRM9kyIU1DaNFAyeuKiVKCKEnTFFwa1oo657yoWskF0VAXUmsmeUtapmlek4Zfojfn3NEPvyYIUT3UqFJHvJSiyv8HMcbzvCgJS9DHM2RSZ8FDq0Zv99ofFCXqpEn9q0mdNalZU9p_PT8y1XtoHrdnL2n-dp7rYHTfeu2MDY8YE0yQ_BTz_ozpUasxHIxOikwPwUw-NRtVONYJVlxxSflfGxO0AQ</recordid><startdate>19980101</startdate><enddate>19980101</enddate><creator>Wahlbeck, Kristian</creator><creator>Ahokas, Antti</creator><creator>Miettinen, Kati</creator><creator>Nikkilä, Heikki</creator><creator>Rimón, Ranan</creator><general>National Institute of Mental Health</general><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7RZ</scope><scope>PSYQQ</scope></search><sort><creationdate>19980101</creationdate><title>Higher Cerebrospinal Fluid Angiotensin-Converting Enzyme Levels in Neuroleptic-Treated Than in Drug-Free Patients With Schizophrenia</title><author>Wahlbeck, Kristian ; Ahokas, Antti ; Miettinen, Kati ; Nikkilä, Heikki ; Rimón, Ranan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a494t-9f249cd016de73b82479e470dd639c2f4b53368f9340aeb69aa293f0f2a15b0d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adult</topic><topic>Analysis of Variance</topic><topic>Angiotensin</topic><topic>Antipsychotic Agents - adverse effects</topic><topic>Antipsychotic Agents - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Blood-Brain Barrier - drug effects</topic><topic>Case-Control Studies</topic><topic>Cerebrospinal Fluid</topic><topic>Drug Therapy</topic><topic>Enzymes</topic><topic>Female</topic><topic>Human</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neuroleptic Drugs</topic><topic>Neuropharmacology</topic><topic>Peptidyl-Dipeptidase A - cerebrospinal fluid</topic><topic>Peptidyl-Dipeptidase A - drug effects</topic><topic>Pharmacology. Drug treatments</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Schizoaffective Disorder</topic><topic>Schizophrenia</topic><topic>Schizophrenia - cerebrospinal fluid</topic><topic>Schizophrenia - drug therapy</topic><topic>Schizophrenia - enzymology</topic><topic>Schizophreniform Disorder</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wahlbeck, Kristian</creatorcontrib><creatorcontrib>Ahokas, Antti</creatorcontrib><creatorcontrib>Miettinen, Kati</creatorcontrib><creatorcontrib>Nikkilä, Heikki</creatorcontrib><creatorcontrib>Rimón, Ranan</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>PsycARTICLES (ProQuest)</collection><collection>ProQuest One Psychology</collection><jtitle>Schizophrenia bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wahlbeck, Kristian</au><au>Ahokas, Antti</au><au>Miettinen, Kati</au><au>Nikkilä, Heikki</au><au>Rimón, Ranan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Higher Cerebrospinal Fluid Angiotensin-Converting Enzyme Levels in Neuroleptic-Treated Than in Drug-Free Patients With Schizophrenia</atitle><jtitle>Schizophrenia bulletin</jtitle><addtitle>Schizophr Bull</addtitle><date>1998-01-01</date><risdate>1998</risdate><volume>24</volume><issue>3</issue><spage>391</spage><epage>397</epage><pages>391-397</pages><issn>0586-7614</issn><eissn>1745-1701</eissn><coden>SCZBB3</coden><abstract>The aim of this study was to replicate our earlier finding of elevated angiotensin-converting enzyme (ACE) in cerebrospinal fluid (CSF) in schizophrenia and to elucidate the role of neuroleptic treatment in this phenomenon. Drug-free and medicated patients with acute schizophrenic psychoses, as well as healthy controls were recruited. Levels of ACE were measured in CSF and serum from 7 drug-free patients, 36 neuroleptic-treated patients, and 19 healthy control subjects. Although ACE levels in CSF did not differ between patients and controls, the drug-free patients showed significantly lower levels than the neuroleptic-treated patients. Serum ACE did not differ between groups. The elevation of CSF ACE may be more prominent in patients with deficit symptoms than in those with mainly psychotic symptoms.
The possible enhancement of CSF ACE production or solubility by neuroleptic treatment is discussed. Elevated ACE levels in CSF may, together with other possible factors, cause polydipsia, stimulate secretion of arginine vasopressin, and even affect neuron growth and differentiation in schizophrenic psychoses.</abstract><cop>Oxford</cop><pub>National Institute of Mental Health</pub><pmid>9718631</pmid><doi>10.1093/oxfordjournals.schbul.a033334</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0586-7614 |
| ispartof | Schizophrenia bulletin, 1998-01, Vol.24 (3), p.391-397 |
| issn | 0586-7614 1745-1701 |
| language | eng |
| recordid | cdi_proquest_journals_614379485 |
| source | MEDLINE; PsycARTICLES; AUTh Library subscriptions: Oxford University Press; Alma/SFX Local Collection; EZB Electronic Journals Library |
| subjects | Adult Analysis of Variance Angiotensin Antipsychotic Agents - adverse effects Antipsychotic Agents - pharmacology Biological and medical sciences Blood-Brain Barrier - drug effects Case-Control Studies Cerebrospinal Fluid Drug Therapy Enzymes Female Human Humans Male Medical sciences Middle Aged Neuroleptic Drugs Neuropharmacology Peptidyl-Dipeptidase A - cerebrospinal fluid Peptidyl-Dipeptidase A - drug effects Pharmacology. Drug treatments Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopharmacology Schizoaffective Disorder Schizophrenia Schizophrenia - cerebrospinal fluid Schizophrenia - drug therapy Schizophrenia - enzymology Schizophreniform Disorder |
| title | Higher Cerebrospinal Fluid Angiotensin-Converting Enzyme Levels in Neuroleptic-Treated Than in Drug-Free Patients With Schizophrenia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T05%3A15%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Higher%20Cerebrospinal%20Fluid%20Angiotensin-Converting%20Enzyme%20Levels%20in%20Neuroleptic-Treated%20Than%20in%20Drug-Free%20Patients%20With%20Schizophrenia&rft.jtitle=Schizophrenia%20bulletin&rft.au=Wahlbeck,%20Kristian&rft.date=1998-01-01&rft.volume=24&rft.issue=3&rft.spage=391&rft.epage=397&rft.pages=391-397&rft.issn=0586-7614&rft.eissn=1745-1701&rft.coden=SCZBB3&rft_id=info:doi/10.1093/oxfordjournals.schbul.a033334&rft_dat=%3Cproquest_cross%3E614379485%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=614379485&rft_id=info:pmid/9718631&rfr_iscdi=true |